Date: 2011-10-25
Type of information: Subvention
Company: Prosensa (The Netherlands)
Investors: AgentschapNL (The Netherlands)
Amount: up to €5 million
Funding type: credit
Planned used: These funds will be used to support further development of a series of preclinical compounds for the treatment of Myotonic Dystrophy type 1 (DM1).
Others: Prosensa has received an innovation credit of up to €5m from AgentschapNL, a subsidiary of the Dutch Ministry of Economic Affairs, Agriculture and Innovation, to support further development of a series of preclinical compounds for the treatment of Myotonic Dystrophy type 1 (DM1). According to the terms of the agreement, Prosensa will receive €940,000 to support the initial stage of the project, with the potential to receive additional funding of up to €5m after successful completion of specific milestones and an initial review in 2012.
Therapeutic area: Rare diseases - Neuromuscular diseases
